.jpg?format=webp&width=780)
To assess the effects of canagliflozin on the incidence of atrial fibrillation/atrial flutter (AF/AFL) and other key cardiorenal outcomes in a pooled analysis of the CANVAS and CREDENCE trials. Overall, 354 participants experienced a first AF/AFL event. Canagliflozin had no detectable effect on AF/AFL compared with placebo. Overall, a significant effect of canagliflozin on the incidence of AF/AFL events could not be shown. However, a possible reduction in AF/AFL events in those with no prior history requires further investigation. Meta‐analysis suggests SGLT2 inhibition reduces AF/AFL incidence.
Like
Save
Share